Chapter 97 - Cannabidiol for the Treatment of Drug Use Disorders R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA in "Handbook of Cannabis and Related Pathologies". "Biology, Pharmacology, Diagnosis, and Treatment", 2017, Pages 939-946 https://doi.org/10.1016/B978-0-12-800756-3.00113-7 Abstract The problematic use of psychoactive substances like alcohol, cannabis, cocaine, amphetamines, heroin, and nicotine carry a series of health, economic, and social costs to individuals and society. Although pharmacological treatments for alcohol, heroin, and nicotine abuse or dependence are available, there is no approved medication for the treatment of cannabis and stimulant dependence. Cannabidiol (CBD), a nonpsychotomimetic cannabinoid present in the cannabis plant, has anxiolytic, antipsychotic, antiepileptic, [...]
Lire la suiteCannabidiol and Canabis Use Disorder María S. García-Gutiérrez, Francisco Navarrete, Adrián Viudez-Martínez, Ani Gasparyan, Esther Caparrós, Jorge Manzanares Chapter, In book : "Cannabis Use Disorders", 2018, pp 31-42 DOI: 10.1007/978-3-319-90365-1_5 Abstract Cannabis use disorders (CUD) represent a serious public health problem in occidental societies. Despite their devastating social, health, and economic impact, to date no pharmacological treatment has been approved for the clinical management of cannabis dependence. Cannabidiol (CBD), one of the main compounds—together with Δ9-THC—present in the plant Cannabis sativa, has been reported to possess anxiolytic, antidepressant, and antipsychotic-like effects and neuroprotective properties. And, contrary to Δ9-THC, CBD does not appear to have addictive properties. Taken [...]
Lire la suiteA Cross-Sectional Study of Cannabidiol Users Jamie Corroon and Joy A. Phillips Cannabis and Cannabinoid Research, 2018, 3, 1, 152-161. https://doi.org/10.1089/can.2018.0006 Abstract Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products can currently be purchased online, over the counter and at Cannabis-specific dispensaries throughout most of the country, despite the fact that CBD is generally deemed a Schedule I controlled substance by the U.S. Drug Enforcement Administration and renounced as a dietary supplement ingredient by the U.S. Food and Drug Administration. Consumer demand for CBD is high and growing, but few studies have examined the [...]
Lire la suiteCannabidiol : a hope to treat non‑motor symptoms of Parkinson’s disease patients Sidra Saleem & Arsalan Anwar European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-01023-y We read an article, “Is Cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms” by Cripp [1], the novel discussion and explanation of the role of cannabidiol (CBD) in Parkinson’s disease (PD) inspired us to write our feedback. We would like to share our views on the role of CBD in the prevention and treatment of movement disorders. CBD is one of the main components of Cannabis sativa investigated previously for its neuroprotective effects. Its mechanism of action [...]
Lire la suiteMolecular Pharmacology of Phytocannabinoids Sarah E. Turner, Claire M. Williams, Leslie Iversen, and Benjamin J. Whalley © Springer International Publishing Switzerland 2017 A.D. Kinghorn, H. Falk, S. Gibbons, J. Kobayashi (eds.), Phytocannabinoids, Progress in the Chemistry of Organic Natural Products 103, 61-100. DOI 10.1007/978-3-319-45541-9_3 Contents 1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteCannabis sativa L. and Nonpsychoactive Cannabinoids : Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer Federica Pellati, Vittoria Borgonetti, Virginia Brighenti, Marco Biagi, Stefania Benvenuti, and Lorenzo Corsi Hindawi, BioMed Research International, 2018, Volume 2018, Article ID 1691428, 15 pages https://doi.org/10.1155/2018/1691428 Abstract In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L., such as Δ9- tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and their effects on inflammation and cancer-related pain.The National Cancer Institute (NCI) currently recognizes medicinal C. sativa as an effective treatment for providing relief in a number of symptoms associatedwith cancer, including pain, [...]
Lire la suiteCannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models Pabitra Hriday Patra, Melissa Barker-Haliski, H. Steve White, Benjamin J. Whalley, Sarah Glyn, Haramrit Sandhu, Nicholas Jones, Michael Bazelot, Claire M. Williams, Alister James McNeish Epilepsia, 2018, 1–12. DOI: 10.1111/epi.14629 Summary Objective : Epilepsy is a progressive neurological disease characterized by recurrent seizures and behavioral comorbidities. We investigated the antiseizure effect of cannabidiol (CBD) in a battery of acute seizure models. Additionally, we defined the disease‐modifying potential of chronic oral administration of CBD on associated comorbidities in the reduced intensity status epilepticus–spontaneous recurrent seizures (RISE‐SRS) model of temporal lobe [...]
Lire la suiteCannabidiol : Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley, and Daniel Friedman Epilepsia, 2014, 55, 6, 791–802, doi: 10.1111/epi.12631 SUMMARY To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders.Wesummarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data [...]
Lire la suiteCANNABIS PEER REVIEW 1964-2016 Over 650 Peer Reviewed Reports & Studies On Cannabis A Free Jeff Prager Publication Health benefits, cancer fighting qualities and many other medicinal advantages can be attributed to the Cannabis Plant. Likewise, diseases and disorders are also related to smoking, vaping and ingesting components of the Cannabis Plant. Cannabis users should be aware and well informed regarding both the positive effects and the negative consequences of regular Cannabis use and this eBook accomplishes that goal by employing over 400 current peer reviewed reports and studies—their findings— with active hyper links to each report. A Free Jeff Prager No-Copyright Publication for [...]
Lire la suiteThe Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats John Shallcross, Peter Hámor, Allison R. Bechard, Madison Romano, Lori Knackstedt and Marek Schwendt Frontiers in Behavioral Neuroscience, May 2019 | Volume 13 | Article 91 ORIGINAL RESEARCH published: 10 May 2019 doi: 10.3389/fnbeh.2019.00091 Post-traumatic stress disorder (PTSD) currently has no FDA-approved treatments that reduce symptoms in the majority of patients. The ability to extinguish fear memory associations is impaired in PTSD individuals. As such, the development of extinction-enhancing pharmacological agents to be used in combination with exposure therapies may benefit the treatment of [...]
Lire la suite